Salivary Duct Carcinoma (SDCA)

Overview

Salivary Duct Carcinoma is an aggressive salivary gland malignancy sitting under SACA (Salivary Carcinoma) in OncoTree. It morphologically resembles ductal carcinoma of the breast and frequently harbors actionable alterations including HER2 amplification and AR expression, enabling targeted therapeutic strategies.

Cohorts in the corpus

• hnc_mskcc_2016 — included as part of the 56 salivary carcinomas (20 “other salivary” beyond ACYC) in 151 recurrent/metastatic head and neck tumors profiled by MSK-IMPACT 410-gene panel PMID:27442865.

Recurrent alterations

• PIK3CA — alterations identified; prompted PI3K-inhibitor trial enrollment in the MSK-IMPACT cohort PMID:27442865.
• HRAS — mutations recurrent in SDCA in the MSK-IMPACT cohort PMID:27442865.
• ERBB2 — actionable alterations (amplification or mutation); one of the most clinically significant findings in SDCA PMID:27442865.
• AR — androgen receptor expression/alteration; actionable in SDCA, enabling androgen deprivation therapy PMID:27442865.
• NF1, ROS1 — structural variants identified in SDCA cases; potential therapeutic targets PMID:27442865.

Subtypes

• Not further subclassified in the corpus.

Therapeutic landscape

• HER2-directed therapy — ERBB2 amplification/mutation in SDCA is a major actionable target; parallels breast ductal carcinoma management rationale PMID:27442865.
• Androgen deprivation therapy — AR expression in SDCA motivates androgen receptor-targeted approaches PMID:27442865.
• PI3K inhibitors — for PIK3CA-altered SDCA; patients enrolled on PI3K-inhibitor basket trials in the MSK-IMPACT cohort PMID:27442865.

Sources

• PMID:27442865 — Morris et al. 2017 (JAMA Oncol). SDCA actionable alterations (PIK3CA, HRAS, ERBB2, AR, NF1, ROS1) identified by MSK-IMPACT in the advanced head and neck cohort.

This page was processed by crosslinker on 2026-05-14.